Diaglip Dosage/Direction for Use

Recommended dose: Treatment with Glimepiride is recommended to be initiated and monitored by a doctor. The dosage of Glimepiride must be the lowest and the dosage will be adjusted to be sufficient to achieve the glycemic control.
Mode of administration: Glimepiride should be taken with breakfast (the first main meal). Do not skip a meal after taking Glimepiride. In case of a dose is forgotten, do not take extra medicine to make up for a missed dose.
Initial dosage and dosage titration: orally 1 mg once daily.
If necessary, the daily dose can be raised. It is recommended that the dose be increased gradually, i.e. at intervals of one to two weeks and according to the following dose steps: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg (and in exceptional cases 8 mg). It is recommended that the increase be guided by regular blood sugar monitoring. And glycated haemoglobin (HbA1c) level should be measured periodically every 3-6 months.
Dose range in patients with well-controlled diabetes: orally 1-4 mg once daily.
Only some patients benefit from daily doses of more than 6 mg. The maximum recommended dosage of the drug is 8 mg daily. The dose must be increased gradually. Any increase should be gradual based on regular blood sugar monitoring. And glycated haemoglobin (HbA1c) level should be measured periodically every 3-6 months.
Use in combination with insulin: Whenever blood sugar levels cannot be controlled adequately with the maximum daily dose of glimepiride, insulin may be given concomitantly. In this case, the current dose of glimepiride remains unchanged. Insulin treatment is started at a low dose, which is subsequently increased stepwise according to the desired blood sugar level. Combined treatment should be initiated under close medical supervision.
Use in combination with metformin: Combination therapy with Glimepiride and metformin may be used in patients who do not respond adequately to the maximal dose of Glimepiride and metformin for each medical product. In order to obtain the desired control blood level, the concomitant Glimepiride and metformin therapy may be used. In this case, the dose of previous medicinal product remains unchanged. The another medicinal product dose is started at a low dose, which is subsequently increased stepwise according to the desired blood sugar level. Combined treatment should be taken under close medical supervision.
Changeover from other oral hypoglycemic agents to DIAGLIP: There is no exact dosage relationship between Glimepiride and other oral blood-sugar-lowering agents. The recommended starting dose is 1 mg Glimepiride per day. After that the desired control of blood glucose may be obtained by adjusting the dose. Carefully monitoring should be taken. Consideration for changeover to Glimepiride the potency and duration of action of the previous blood-sugar-lowering agent has to be taken in order to avoid the risk of hypoglycemia.
Secondary dosage adjustment: Long term Glimepiride uses and control of diabetes improves. Secondary dosage adjustment should be considered by a physician. Owing to the sensitivity of insulin increases and to avoid an excessive reduction in blood sugar (hypoglycemia) then properly dose reduction or cessation of DIAGLIP therapy must be considered.
Hepatic impairment and renal impairment: Because Glimepiride is eliminated by renal excretion following metabolism in the liver. Initial dosing of the drug in patients with renal or hepatic impairment should be conservative to avoid hypoglycemic reaction; adults initially should receive 1 mg of Glimepiride once daily. The dosage may be titrated upward based on fasting glucose concentration.